schliessen

Filtern

 

Bibliotheken

NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial–mesenchymal transition in hepatocellular carcinoma cells

Doxorubicin-based therapy is not effective for the treatment of hepatocellular carcinomas (HCCs), which often undergo epithelial–mesenchymal transition (EMT) during tumor progression. Activation of signal transducer and activator of transcription 3 (STAT3) is associated with chemosensitivity and may... Full description

Journal Title: Cancer Letters 28 December 2012, Vol.325(2), pp.207-213
Main Author: Hu, Qi-Da
Other Authors: Chen, Wei , Yan, Tian-Lian , Ma, Tao , Chen, Cong-Lin , Liang, Chao , Zhang, Qi , Xia, Xue-Feng , Liu, Hao , Zhi, Xiao , Zheng, Xiao-Xiao , Bai, Xue-Li , Yu, Xia-Zhen , Liang, Ting-Bo
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0304-3835 ; E-ISSN: 1872-7980 ; DOI: 10.1016/j.canlet.2012.07.003
Link: https://www.sciencedirect.com/science/article/pii/S0304383512003862
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_canlet_2012_07_003
title: NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial–mesenchymal transition in hepatocellular carcinoma cells
format: Article
creator:
  • Hu, Qi-Da
  • Chen, Wei
  • Yan, Tian-Lian
  • Ma, Tao
  • Chen, Cong-Lin
  • Liang, Chao
  • Zhang, Qi
  • Xia, Xue-Feng
  • Liu, Hao
  • Zhi, Xiao
  • Zheng, Xiao-Xiao
  • Bai, Xue-Li
  • Yu, Xia-Zhen
  • Liang, Ting-Bo
subjects:
  • Hepatocellular Carcinoma
  • Signal Transducer and Activator of Transcription 3
  • Epithelial–Mesenchymal Transition
  • Doxorubicin
  • NSC 74859
  • Medicine
ispartof: Cancer Letters, 28 December 2012, Vol.325(2), pp.207-213
description: Doxorubicin-based therapy is not effective for the treatment of hepatocellular carcinomas (HCCs), which often undergo epithelial–mesenchymal transition (EMT) during tumor progression. Activation of signal transducer and activator of transcription 3 (STAT3) is associated with chemosensitivity and may contribute to EMT during HCC chemotherapy. Low doses of NSC 78459 (a novel STAT3 inhibitor) have little effect on HCC cell proliferation, but efficiently inhibit STAT3. HuH-7, Hep3B, and HepG2 cells, with epithelial phenotypes, show significantly enhanced doxorubicin cytotoxicity following co-treatment with NSC 74859, whereas mesenchymal SNU-449 cells show no such enhancement. NSC 74859 inhibits STAT3 activity and suppressed doxorubicin-induced EMT in epithelial HCC cells. siRNA-mediated STAT3 knockdown resulted in EMT inhibition, which led to attenuation of NSC 74859-mediated chemosensitivity. Our data indicate NSC 74859 co-administration enhances doxorubicin cytotoxicity...
language: eng
source:
identifier: ISSN: 0304-3835 ; E-ISSN: 1872-7980 ; DOI: 10.1016/j.canlet.2012.07.003
fulltext: fulltext
issn:
  • 0304-3835
  • 03043835
  • 1872-7980
  • 18727980
url: Link


@attributes
ID1371137405
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_canlet_2012_07_003
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_canlet_2012_07_003
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94CK
104G.
117-5
128P~
139JM
14AABNK
15AAEDT
16AAKOC
17AAOAW
18AAQFI
19ABBQC
20ABFNM
21ABGSF
22ABYKQ
23ACDAQ
24ACIUM
25ACRLP
26ADUVX
27AEHWI
28AEKER
29AEVXI
30AFKWA
31AFTJW
32AFXIZ
33AGHFR
34AGUBO
35AGYEJ
36AIKHN
37AITUG
38AJBFU
39AJOXV
40AJRQY
41AJUYK
42AMFUW
43ANZVX
44BLXMC
45BNPGV
46DOVZS
47EO8
48EO9
49EP2
50EP3
51FDB
52FIRID
53FNPLU
54G-Q
55GBLVA
56J1W
57KOM
58LCYCR
59OAUVE
60OC~
61OO-
62P-8
63P-9
64PC.
65Q38
66RPZ
67SCC
68SDF
69SDG
70SDP
71SEL
72SES
73SSH
74SSU
75SSZ
76T5K
77Z5R
78~G-
pqid1038071960
galeid301423553
display
typearticle
titleNSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial–mesenchymal transition in hepatocellular carcinoma cells
creatorHu, Qi-Da ; Chen, Wei ; Yan, Tian-Lian ; Ma, Tao ; Chen, Cong-Lin ; Liang, Chao ; Zhang, Qi ; Xia, Xue-Feng ; Liu, Hao ; Zhi, Xiao ; Zheng, Xiao-Xiao ; Bai, Xue-Li ; Yu, Xia-Zhen ; Liang, Ting-Bo
ispartofCancer Letters, 28 December 2012, Vol.325(2), pp.207-213
identifier
subjectHepatocellular Carcinoma ; Signal Transducer and Activator of Transcription 3 ; Epithelial–Mesenchymal Transition ; Doxorubicin ; NSC 74859 ; Medicine
descriptionDoxorubicin-based therapy is not effective for the treatment of hepatocellular carcinomas (HCCs), which often undergo epithelial–mesenchymal transition (EMT) during tumor progression. Activation of signal transducer and activator of transcription 3 (STAT3) is associated with chemosensitivity and may contribute to EMT during HCC chemotherapy. Low doses of NSC 78459 (a novel STAT3 inhibitor) have little effect on HCC cell proliferation, but efficiently inhibit STAT3. HuH-7, Hep3B, and HepG2 cells, with epithelial phenotypes, show significantly enhanced doxorubicin cytotoxicity following co-treatment with NSC 74859, whereas mesenchymal SNU-449 cells show no such enhancement. NSC 74859 inhibits STAT3 activity and suppressed doxorubicin-induced EMT in epithelial HCC cells. siRNA-mediated STAT3 knockdown resulted in EMT inhibition, which led to attenuation of NSC 74859-mediated chemosensitivity. Our data indicate NSC 74859 co-administration enhances doxorubicin cytotoxicity...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383512003862$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Hu, Qi-Da
1Chen, Wei
2Yan, Tian-Lian
3Ma, Tao
4Chen, Cong-Lin
5Liang, Chao
6Zhang, Qi
7Xia, Xue-Feng
8Liu, Hao
9Zhi, Xiao
10Zheng, Xiao-Xiao
11Bai, Xue-Li
12Yu, Xia-Zhen
13Liang, Ting-Bo
titleNSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial–mesenchymal transition in hepatocellular carcinoma cells
description

Doxorubicin-based therapy is not effective for the treatment of hepatocellular carcinomas (HCCs), which often undergo epithelial–mesenchymal transition (EMT) during tumor progression. Activation of signal transducer and activator of transcription 3 (STAT3) is associated with chemosensitivity and may contribute to EMT during HCC chemotherapy. Low doses of NSC 78459 (a novel STAT3 inhibitor) have little effect on HCC cell proliferation, but efficiently inhibit STAT3.

HuH-7, Hep3B, and HepG2 cells, with epithelial phenotypes, show significantly enhanced doxorubicin cytotoxicity following co-treatment with NSC 74859, whereas mesenchymal SNU-449 cells show no such enhancement. NSC 74859 inhibits STAT3 activity and suppressed doxorubicin-induced EMT in epithelial HCC cells. siRNA-mediated STAT3 knockdown resulted in EMT inhibition, which led to attenuation of NSC 74859-mediated chemosensitivity. Our data indicate NSC 74859 co-administration enhances doxorubicin cytotoxicity...

subject
0Hepatocellular Carcinoma
1Signal Transducer and Activator of Transcription 3
2Epithelial–Mesenchymal Transition
3Doxorubicin
4NSC 74859
5Medicine
general
0English
1Elsevier Ireland Ltd
210.1016/j.canlet.2012.07.003
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_canlet_2012_07_003
issn
00304-3835
103043835
21872-7980
318727980
rsrctypearticle
creationdate2012
addtitleCancer Letters
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94CK
104G.
117-5
128P~
139JM
14AABNK
15AAEDT
16AAKOC
17AAOAW
18AAQFI
19ABBQC
20ABFNM
21ABGSF
22ABYKQ
23ACDAQ
24ACIUM
25ACRLP
26ADUVX
27AEHWI
28AEKER
29AEVXI
30AFKWA
31AFTJW
32AFXIZ
33AGHFR
34AGUBO
35AGYEJ
36AIKHN
37AITUG
38AJBFU
39AJOXV
40AJRQY
41AJUYK
42AMFUW
43ANZVX
44BLXMC
45BNPGV
46DOVZS
47EO8
48EO9
49EP2
50EP3
51FDB
52FIRID
53FNPLU
54G-Q
55GBLVA
56J1W
57KOM
58LCYCR
59OAUVE
60OC~
61OO-
62P-8
63P-9
64PC.
65Q38
66RPZ
67SCC
68SDF
69SDG
70SDP
71SEL
72SES
73SSH
74SSU
75SSZ
76T5K
77Z5R
78~G-
startdate20121228
enddate20121228
lsr40Cancer Letters, 28 December 2012, Vol.325 (2), pp.207-213
doi10.1016/j.canlet.2012.07.003
citationpf 207 pt 213 vol 325 issue 2
lsr30VSR-Enriched:[galeid, pqid]
sort
titleNSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial–mesenchymal transition in hepatocellular carcinoma cells
authorHu, Qi-Da ; Chen, Wei ; Yan, Tian-Lian ; Ma, Tao ; Chen, Cong-Lin ; Liang, Chao ; Zhang, Qi ; Xia, Xue-Feng ; Liu, Hao ; Zhi, Xiao ; Zheng, Xiao-Xiao ; Bai, Xue-Li ; Yu, Xia-Zhen ; Liang, Ting-Bo
creationdate20121228
lso0120121228
facets
frbrgroupid8599209927932996491
frbrtype5
newrecords20190904
languageeng
topic
0Hepatocellular Carcinoma
1Signal Transducer and Activator of Transcription 3
2Epithelial–Mesenchymal Transition
3Doxorubicin
4NSC 74859
5Medicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Hu, Qi-Da
1Chen, Wei
2Yan, Tian-Lian
3Ma, Tao
4Chen, Cong-Lin
5Liang, Chao
6Zhang, Qi
7Xia, Xue-Feng
8Liu, Hao
9Zhi, Xiao
10Zheng, Xiao-Xiao
11Bai, Xue-Li
12Yu, Xia-Zhen
13Liang, Ting-Bo
jtitleCancer Letters
creationdate2012
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Hu
1Chen
2Yan
3Ma
4Liang
5Zhang
6Xia
7Liu
8Zhi
9Zheng
10Bai
11Yu
aufirst
0Qi-Da
1Wei
2Tian-Lian
3Tao
4Cong-Lin
5Chao
6Qi
7Xue-Feng
8Hao
9Xiao
10Xiao-Xiao
11Xue-Li
12Xia-Zhen
13Ting-Bo
auinitQ
auinit1Q
au
0Hu, Qi-Da
1Chen, Wei
2Yan, Tian-Lian
3Ma, Tao
4Chen, Cong-Lin
5Liang, Chao
6Zhang, Qi
7Xia, Xue-Feng
8Liu, Hao
9Zhi, Xiao
10Zheng, Xiao-Xiao
11Bai, Xue-Li
12Yu, Xia-Zhen
13Liang, Ting-Bo
atitleNSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial–mesenchymal transition in hepatocellular carcinoma cells
jtitleCancer Letters
risdate20121228
volume325
issue2
spage207
epage213
pages207-213
issn0304-3835
eissn1872-7980
formatjournal
genrearticle
ristypeJOUR
abstract

Doxorubicin-based therapy is not effective for the treatment of hepatocellular carcinomas (HCCs), which often undergo epithelial–mesenchymal transition (EMT) during tumor progression. Activation of signal transducer and activator of transcription 3 (STAT3) is associated with chemosensitivity and may contribute to EMT during HCC chemotherapy. Low doses of NSC 78459 (a novel STAT3 inhibitor) have little effect on HCC cell proliferation, but efficiently inhibit STAT3.

HuH-7, Hep3B, and HepG2 cells, with epithelial phenotypes, show significantly enhanced doxorubicin cytotoxicity following co-treatment with NSC 74859, whereas mesenchymal SNU-449 cells show no such enhancement. NSC 74859 inhibits STAT3 activity and suppressed doxorubicin-induced EMT in epithelial HCC cells. siRNA-mediated STAT3 knockdown resulted in EMT inhibition, which led to attenuation of NSC 74859-mediated chemosensitivity. Our data indicate NSC 74859 co-administration enhances doxorubicin cytotoxicity...

pubElsevier Ireland Ltd
doi10.1016/j.canlet.2012.07.003
lad01Cancer Letters
date2012-12-28